#15 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
D.C. is tightening cannabis advertising to protect young people while Virginia is building a regulated market from scratch—both developments show cannabis policy is maturing toward responsible frameworks.
Arizona state senators approved measures to criminalize ‘excessive’ marijuana levels while driving, establishing impairment thresholds for cannabis-intoxicated driving. The legislation represents the evolving challenge of setting scientifically valid DUI standards for cannabis, as THC metabolites persist in the body long after impairment fades. Unlike alcohol’s well-established BAC limits, cannabis impairment testing remains controversial—blood THC levels don’t reliably correlate with actual impairment. The bill balances public safety with protecting lawful cannabis users from unfair prosecution based solely on metabolite presence.
“D.C. refining its market while Virginia builds one next door perfectly illustrates the future of cannabis on the East Coast: messy, state-by-state, but unmistakably moving toward regulation over prohibition.”
ARIZONA’S CANNABIS DUI CHALLENGE
Senators approved ‘excessive’ marijuana DUI measures—wading into one of the most complex cannabis policy challenges. Blood THC doesn’t correlate with impairment like BAC does for alcohol. Metabolites persist for days/weeks after effects end.
Arizona’s bill establishes an ‘excessive’ threshold rather than zero-tolerance. Whether the level accurately reflects impairment is debatable. The field needs behavioral testing, saliva screening, and improved roadside tools. Political pressure to ‘do something’ often outpaces the science for doing the right thing.
Have thoughts on this? Share it:
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →